Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

SPACTORY, revolutionising pharmaceutical development and manufacturing through microgravity

Objective

Over 2,000 R&D experiments have been done in Space until now. Space near-zero gravity yields biochemical crystals orders of magnitude more defined, pure, uniform, and precise than in terrestial environments. The low-gravity accelerates the development and preclinical testing of complex molecules –e.g. proteins- and unleashes the potential of innovative high-value mAbs therapies, saving patient’s lives and improving their QoL.
To make it real, after 11 space missions, SPACEPHARMA is committed to bringing the first mAbs factory to Space. MOTI, the main SPACTORY building block, brings accessible, scalable, and affordable microgravity manufacturing controlled from Earth and able to fly in any satellite compatible with any launcher. For our customers, the pharma industry, it means shorter time to Space, faster market access and affordable drug development. For SPACEPHARMA, it is a paradigm shift from drug R&D to manufacturing. For EU, it means leading the spatial race in drug development.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

SPACEPHARMA R&D ISRAEL LTD
Net EU contribution
€ 2 184 052,50
Address
Abba Eban 1
4672519 Herzliya Pituach
Israel
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data